New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
07:26 EDTLCILannett shares should be bought on weakness, says Oppenheimer
After Lannett reduced its Q4 guidance but provided higher than expected FY15 revenue guidance based on price increases it has implemented, Oppenheimer believes that investors should be pleased with the overall guidance. The firm keeps a $49 price target and Outperform rating on the stock.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
16:36 EDTLCILannett up 9.1% after announcing that it will acquire Kremers Urban
16:35 EDTLCILannett to acquire Kremers Urban Pharmaceuticals For $1.23B
Subscribe for More Information
16:34 EDTLCILannett to acquire Kremers Urban Pharmaceuticals For $1.23B
August 26, 2015
08:44 EDTLCILannett steady execution offers compelling upside, says Susquehanna
Susquehanna noted Lannett delivered solid Q2 results and outlook and believes its stock price is undervaluing the upside potential from new products and business development. The firm also sees the potential for multiple expansion if volume trends remain steady. Susquehanna reiterated its Positive rating but lowered its price target to $70 from $75 on Lannett shares.
August 25, 2015
16:08 EDTLCILannett sees FY16 CapEx $60M-$70M
Which includes $30M to continue the partial fit-out of company-owned buildings. Sees FY16 gross margin as a percentage of net sales of approximately 71%-73%; R&D expense in the range of $33M-$35M; SG&A expense ranging from $57M-$59M, which includes approximately $5M in acquisition-related expenses; The full year effective tax rate to be in the range of 34%-35%.
16:06 EDTLCILannett sees FY16 revenue $425M-$435M, consensus $433.55M
16:05 EDTLCILannett reports Q4 EPS 91c, consensus 86c
Reports Q4 revenue $99.3M, consensus $97.62M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use